secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENXBIO Inc. (RGNX)
CIK:        0001590877
Form:       8-K
Filed at:   2026-09-23T20:05:14+00:00
Accession:  0001193125-26-399377
Event type: litigation
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

REGENXBIO settles patent litigation with Sarepta for $39M payment
-----------------------------------------------------------------

- Sarepta will pay $39.0 million to REGENXBIO within 10 days of settlement effective date (Sept 23, 2026).
- Settlement resolves all patent infringement litigation over U.S. Patent Nos. 10,526,617 and 11,680,274 related to ELEVIDYS (SRP-9001).
- Parties terminate litigation with prejudice; REGENXBIO and UPenn release current claims and covenant not to sue on AAVrh74-based products.
- Covenant covers existing ELEVIDYS form and AAVrh74 capsid sequence, but does not extend to other gene therapy aspects.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590877/000119312526399377/0001193125-26-399377-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590877/000119312526399377/rgnx-20260923.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-399377

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer